CASI Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About CASI Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for hematology-oncology, autoimmune diseases, and organ transplant rejection. Following corporate restructuring and the divestiture of its China-focused pipeline rights, the firm primarily operates as a clinical-stage drug developer advancing CID-103, an anti-CD38 monoclonal antibody. It also holds rights to therapies including EVOMELA, FOLOTYN, CNCT19, and CB-5339, alongside generic melphalan. Products are targeted toward medical institutions and oncology patients, with distribution agreements spanning pharmaceutical distributors and healthcare partners.
The company has conducted primary commercial and clinical operations in China through subsidiaries CASI China and CASI Wuxi, while pursuing global clinical development for core drug candidates across the United States, Europe, and Asia. In China, operations have utilized over two hundred staff members, including an oncology commercial team. Corporate principal executive offices are situated in Beijing, China, with a registered office in the Cayman Islands and an agent office in California.
Summary of the business section of CASI Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CASI Pharmaceuticals, Inc.
- Founded
- 1991
- Headquarters
- Beijing, F4
- Address
- 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District 100025
- Phone
- 86 10 6561 8789
- Website
- casipharmaceuticals.com
- Employees
- 214, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- KPMG Huazhen LLP, Beijing, China
Stock & identifiers
- Ticker
- CASIF
- Exchange
- OTC
- IPO date
- Jun 12, 1996
- Shares outstanding
- 21M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-10 reverse, Jun 2, 2022; 1-for-11 reverse, Jul 1, 2010
- SEC CIK
- 1962738
- CUSIP
- G1933S101
- ISIN
- USG1933S1018
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Wei R. Gao | General Counsel | – |
| Kun Qian | Global Controller | – |
| Hai Huang | Global Chief Commercial Ofcr | – |
| Chunhua Wang | Chief Operating Officer | – |
| Alexander A. Zukiwski | Global Chief Medical Officer | – |
| Thomas Folinsbee | Director | – |
| Xuebo Zeng | Director | – |
| Barbara Helene Hannelore Krebs-Pohl | Director | – |
| Alex Wu | Director | 34,168 |
| James Huang | Director | 4,529,956 |
| Wei-Wu He | Director | 2,592,301 |
Employees
Headcount reported in annual reports
“We had 243, 233 and 214 employees as of December 31, 2023, 2024 and 2025, respectively.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 23, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Apr 21, 2026 | Late filing | Notification of late filing |
| Mar 27, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 14, 2023 | Name change | Name changed from CASI Pharmaceuticals Holdings, Inc. to CASI Pharmaceuticals, Inc. |
| Jan 31, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |